ClinicalTrials.gg
CompletedNCT04333472Updated Apr 22, 2022

Piclidenoson for Treatment of COVID-19

A Phase 2 interventional study of Piclidenoson and Placebo in COVID-19 and Coronavirus Infection, sponsored by Can-Fite BioPharma. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in COVID-19 with a site in Bulgaria — 5 open to participants now, 5 under way, 5 of them phase 3. COVID-19 · Bulgaria.

Enrollment
23rd of 25
6 · median 290
Started
2021
with 11 others
Phase 2
8 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
1 of 27
Can-Fite BioPharma

Among the 27 studies in COVID-19 with a site in Bulgaria, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 12 that started in 2021, is one of 8 in phase 2, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

5 of the 27 studies in COVID-19 with a site in Bulgaria are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in COVID-19 with a site in Bulgaria, or all of them as a file.
02

Study summary

Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28 days.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, pilot trial of piclidenoson 2 mg Q12H added to SSC, compared to placebo plus SSC, in a population of hospitalized subjects with "Moderate" or "Severe" COVID-19 per U.S. National Institutes of Health (NIH) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (2020). Subjects will be randomized according to a 1:1 ratio to one of the trial arms, and treated for up to 28 days, at the discretion of the Investigator. Piclidenoson 2 mg and placebo are supplied as matching tablets for oral administration.

Following initial diagnosis of COVID-19, and after having provided informed consent, subjects will be randomized according to 1:1 ratio to one of the trial arms on Day 0. SSC will be implemented and documented for all subjects, and maintained throughout the treatment period.

Vital signs (temperature, blood pressure, pulse rate per minute, respiratory rate per minute, oxygen saturation (SpO2), and PaO2/FiO2) of subjects will be monitored twice daily according to SSC. Parameters of clinical, respiratory, and vital status will be collected daily. Viral shedding will be assessed on a regular basis. Samples for pharmacokinetic (PK) analysis will be collected on Day 4.

Efficacy of piclidenoson will be assessed by clinical, respiratory, and virologic parameters. Safety and tolerability of piclidenoson will be assessed by adverse event (AE) monitoring, vital signs assessment, electrocardiograms (ECGs), and clinical laboratory tests (complete blood count (CBC) and extended chemistry panel). Adverse events will be graded by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).

03

Conditions studied

  • COVID-19
  • Coronavirus Infection

Keywords

  • Piclidenoson
  • CF101
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized subjects 18 to 85 years of age, inclusive
  2. Able and willing to sign
  3. Molecular (RT-PCR) diagnosis of SARS-CoV-2 infection
  4. Moderate or Severe illness per NIH COVID-19 Treatment Guidelines:

    "Moderate" Illness:

    • Symptoms such as cough, fever, sore throat, malaise, myalgias, headache; and
    • Evidence of lower respiratory tract disease by clinical assessment and/or imaging; and
    • SpO2 >93% on room air at sea level

    "Severe" Illness, including any of the following:

    • Respiratory rate >30 breaths/minute; or
    • SpO2 ≤93% on room air at sea level; or
    • Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) \<300; or
    • Lung infiltrates >50% of pulmonary volume on imaging
  5. Female subjects must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of product
  6. Female subjects of and male subjects with partners of childbearing potential must agree to use adequate methods of during the study and through 90 days after the last dose of study medication. Female subjects of childbearing potential are all those except subjects who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year .

    1. For females: 2 of the following contraceptive methods, with at least 1 being a barrier method:

      • Hormonal contraceptives for at least 27 days before dosing
      • Intrauterine device (IUD) in place at least 27 days before dosing
      • Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening
      • Surgical sterilization of the partner (vasectomy at least 1 month before screening)
      • Female subjects must have a negative urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of investigational product.
    2. For males: Surgical sterilization (vasectomy at least 1 month before screening) or double barrier methods.

Exclusion criteria

Exclusion Criteria

    1. "Critical" Illness, per NIH COVID-19 Treatment Guidelines, including any of the following:

      • Respiratory failure; or
      • Septic shock; or
      • Multiple organ dysfunction
  1. Subjects who require mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  2. Participation in another clinical trial concurrently
  3. Concurrent treatment with immunomodulators or anti-rejection drugs
  4. Nursing women, pregnant women, women of who do not want adequate
  5. History of any of the following diseases or conditions:

    • Advanced or decompensated liver disease (including presence or history of bleeding varices, ascites, encephalopathy, or hepato-renal syndrome)
    • Inability to swallow tablets, or gastrointestinal disease which could interfere with the absorption of piclidenoson
    • Any within 5 years before screening; exceptions are superficial dermatologic malignancies (e.g., squamous cell or basal cell skin cancer treated with curative intent)
    • Cardiomyopathy, significant ischemic cardiac or cerebrovascular disease (including history of angina, myocardial infarction, or interventional procedure for coronary artery disease), or cardiac rhythm disorder
    • interval on an average of triplicate ECGs >450 milliseconds (msec) for males or >470 msec for females (except when QT prolongation is associated with right or left bundle branch block, in which case enrollment is allowed)
    • Any condition which increases proarrhythmic risk, including hypokalemia, hypomagnesemia, congenital Long QT Syndrome
    • Ongoing or planned use of a concomitant medication that is on the CredibleMeds list of drugs known to cause Torsades de Pointes unless the subject can be screened and monitored under the guidelines proposed by Giudicessi (2020)
    • Pancreatitis
    • Severe or uncontrolled psychiatric disorder, e.g., depression, manic condition, psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and relapse of substance abuse
    • Active seizure disorder defined by either an untreated seizure disorder or continued seizure activity within the preceding year despite treatment with anti-seizure medication
    • Bone marrow or solid organ transplantation
    • Any serious condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed
  6. Any of the following abnormal laboratory tests:

    • count \<90,000 cells/mm3
    • (ANC) \<1,500 cells/mm3
    • Estimated (CrCl) \<50 mL/min by Cockroft-Gault formulation
    • level ≥2.5 mg/dL unless due to Gilbert's syndrome
    • or ALT level ≥3X the
    • Serum albumin level \<3.0 g/dL
    • (INR) ≥1.5 (except subjects maintained on anticoagulant medications)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Piclidenoson

    Piclidenoson 2 mg every 12 hours orally added to standard of care

    Drug: Piclidenoson

  • Placebo comparator
    Placebo

    Placebo every 12 hours orally added to standard of care

    Drug: Placebo

Interventions

  • Piclidenoson 2 mg orally every 12 hours for up to 28 days

    Also known as: CF101

  • DrugPlacebo

    Placebo orally every 12 hours for up to 28 days

06

What researchers measure

Primary outcomes

  1. Proportion of subjects alive and free of respiratory failure

    Proportion of subjects alive and free of respiratory failure (defined as need for non-invasive or invasive mechanical ventilation, high-flow oxygen, or extracorporeal membrane oxygenation) at Day 29

    Time frame: 29 days

  2. Proportion of subjects discharged home alive

    Proportion of subjects alive and discharged to home without need for supplemental oxygen at Day 29

    Time frame: 29 days

  3. Treatment-emergent adverse events (AEs)

    Proportion of patients experiencing AEs

    Time frame: 29 days

Secondary outcomes

  1. Clinical status

    • Clinical status at Day 29 on NIAID 8-point ordinal scale (NIH 2020): 1. Not hospitalized, no limitations 2. Not hospitalized, with limitations 3. Hospitalized, no active medical problems 4. Hospitalized, not on oxygen 5. Hospitalized, on oxygen 6. Hospitalized, on high-flow oxygen or noninvasive mechanical ventilation 7. Hospitalized, on mechanical ventilation or ECMO 8. Death

    Time frame: 29 days

  2. Time to improvement

    Time (days) to improvement of 2 points on 7-point ordinal clinical scale

    Time frame: 29 days

  3. Incidence of mechanical ventilation

    Proportion of patients who require mechanical ventilation

    Time frame: 29 days

  4. Ventilator-free days

    Ventilator-free days to Day 29

    Time frame: 29 days

  5. Incidence of Intensive Care Unit (ICU) admission

    Proportion of patients who require ICU admission

    Time frame: 29 days

  6. Duration of ICU stay

    Duration (days) of ICU stay

    Time frame: 29 days

  7. Time to hospital discharge

    Time (days) to hospital discharge

    Time frame: 29 days

  8. Duration of need for supplemental oxygen

    Duration (days) of need for supplemental oxygen

    Time frame: 29 days

  9. Time to virus negativity

    Time (days) to virus negativity by RT-PCR, defined as absence of SARS CoV 2 on 2 consecutive days of sampling

    Time frame: 29 days

  10. SARS-CoV-2 viral load

    SARS-CoV-2 viral load (number of copies) by quantitative RT-PCR

    Time frame: 29 days

  11. AEs leading to withdrawal

    Proportion of patients experiencing AEs leading to early discontinuation of trial treatment

    Time frame: 29 days

  12. Treatment-emergent serious AEs (SAEs)

    Proportion of patients experiencing SAEs

    Time frame: 29 days

  13. Treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ECGs)

    Proportion of patients experiencing treatment-emergent changes in clinical laboratory parameters or ECGs

    Time frame: 29 days

  14. Incidence of meeting safety-related stopping rules

    Proportion of patients who meet study safety-related stopping rules

    Time frame: 29 days

  15. Pharmacokinetics of piclidenoson in this patient population

    Plasma concentrations over time of piclidenoson

    Time frame: 5 days

  16. Serum cytokine levels

    Change from baseline in serum concentrations of cytokines

    Time frame: 29 days

07

Study locations

6 sites
  • II Multiprofile Hospital for Active Treatment - Sofia EAD
    Sofia, Bulgaria
  • IV Multiprofile Hospital for Active Treatment - Sofia EAD
    Sofia, Bulgaria
  • Hadassah Medical Center
    Jerusalem, Israel
  • Shaare Zedek Medical Center
    Jerusalem, Israel
  • Clinical Hospital for Infectious Diseases "St. Parascheva" Iasi
    Iaşi, Romania
  • "Sfantul Ioan cel Nou" County Emergency Hospital Suceava
    Suceava, Romania
08

References and documents

Publications

  • Fishman P, Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol. 2016 Sep;35(9):2359-62. doi: 10.1007/s10067-016-3202-4. Epub 2016 Feb 17. PubMed 26886128 ↗
  • Cohen S, Fishman P. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. Drug Des Devel Ther. 2019 Jan 30;13:491-497. doi: 10.2147/DDDT.S195294. eCollection 2019. PubMed 30787591 ↗

Related links

Individual participant data

Plan to share: Yes — To be determined

Supporting information: Study protocol, Clinical study report

Time frame: January 2021, indefinitely

Access criteria: To be determined

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Mar 2022, 14 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 14 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 3, 2020
StartActual
Jan 6, 2021
Primary completionActual
Mar 6, 2022
CompletionActual
Apr 21, 2022
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04333472
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Jan 6, 2021
Primary completion
Mar 6, 2022
Completion
Apr 21, 2022
Last update
Apr 22, 2022

Study contacts

Zivit Harpaz
study director · Can-Fite BioPharma Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion